drugset / Trial / NCT04925973
Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management
Phase 2
Active not recruiting
24 enrolled
McMaster University
McGill University · collabUniversity of Alberta · collabUniversity of British Columbia · collabUniversity of Manitoba · collab
NaSingle-groupOpen-labelTreatment
Summary
The TRIUMPH study was designed to build on the existing literature by studying the efficacy of tofacitinib in hospitalized patients with acute severe ulcerative colitis. This trial will provide evidence for a possible new indication for the use of tofacitinib.
Timeline
- Start
- 2021-06-01
- Primary completion
- 2023-12
- Completion
- 2023-12
Publications
- Narula N, Pray C, Hamam H, Peerani F, Hansen T, Bessissow T, Bressler B, Arun A, Schmit M, Castelli J, Marshall JK. Tofacitinib for Hospitalized Acute Severe Ulcerative Colitis Management (The TRIUMPH Study). Crohns Colitis 360. 2025 Feb 15;7(1):otaf013. doi: 10.1093/crocol/otaf013. eCollection 2025 Jan.
- Narula N, Hamam H, Peerani F, Bessissow T, Bressler B, Dulai PS; Canadian IBD Research Consortium; Canadian IBD Research Consortium. Resolution of Rectal Bleeding by Day 7 in Acute Severe Ulcerative Colitis Is Prognostic for Postdischarge Corticosteroid-Free Clinical Remission and Endoscopic Improvement. Am J Gastroenterol. 2024 Sep 1;119(9):1939-1942. doi: 10.14309/ajg.0000000000002860. Epub 2024 May 8.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tofacitinib | Small molecule | 10 mg | Oral |